R Pontremoli
Overview
Explore the profile of R Pontremoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
634
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferri N, Corsini A, Pontremoli R
Eur Rev Med Pharmacol Sci
. 2022 Dec;
26(22):8204.
PMID: 36459001
Correction to: European Review for Medical and Pharmacological Sciences 2022; 26 (20): 7482-7492. DOI: 10.26355/eurrev_202210_30018-PMID: 36314318, published online on October 28, 2022. After publication, the authors applied some corrections to...
2.
Ferri N, Corsini A, Pontremoli R
Eur Rev Med Pharmacol Sci
. 2022 Oct;
26(20):7482-7492.
PMID: 36314318
Objective: The aim of the study was to review the literature on clinical pharmacology of lercanidipine and experimental and clinical evidence and evaluate its ability to reduce proteinuria and preserve...
3.
Russo G, Giandalia A, Ceriello A, Di Bartolo P, Di Cianni G, Fioretto P, et al.
Diabetes Res Clin Pract
. 2022 Sep;
192:110092.
PMID: 36167264
Objective: To develop and validate a model for predicting 5-year eGFR-loss in type 2 diabetes mellitus (T2DM) patients with preserved renal function at baseline. Research Design And Methods: A cohort...
4.
Piscitelli P, Mangiacotti A, Marchese N, Greco E, DErrico M, Massa V, et al.
Eur Rev Med Pharmacol Sci
. 2020 Sep;
24(17):9063-9070.
PMID: 32964997
Objective: Prior cardiovascular event and kidney dysfunction are both strong risk factors for coronary artery disease. The aim of this study is to assess coronary atherosclerotic burden in a large...
5.
Maloberti A, Giannattasio C, Bombelli M, Desideri G, Cicero A, Muiesan M, et al.
High Blood Press Cardiovasc Prev
. 2020 Mar;
27(2):121-128.
PMID: 32157643
The latest European Guidelines of Arterial Hypertension have officially introduced uric acid evaluation among the cardiovascular risk factors that should be evaluated in order to stratify patient's risk. In fact,...
6.
Arca M, Borghi C, Pontremoli R, Ferrari G, Colivicchi F, Desideri G, et al.
Nutr Metab Cardiovasc Dis
. 2018 Feb;
28(3):197-205.
PMID: 29397253
Aims: This review aims to describe the pathogenic role of triglycerides in cardiometabolic risk, and the potential role of omega-3 fatty acids in the management of hypertriglyceridemia and cardiovascular disease....
7.
Degli Esposti L, Desideri G, Saragoni S, Buda S, Pontremoli R, Borghi C
Nutr Metab Cardiovasc Dis
. 2016 Aug;
26(10):951-61.
PMID: 27555289
Background And Aim: Chronic hyperuricemia is responsible for a relevant burden of articular diseases and cardio-nephrometabolic disorders. We evaluated the effect of high serum uric acid (SUA) levels on hospitalization...
8.
Ratto E, Viazzi F, Verzola D, Bonino B, Gonnella A, Parodi E, et al.
J Hum Hypertens
. 2015 Jun;
30(3):158-63.
PMID: 26108365
Metabolic syndrome (MS) has been shown to predict cardiovascular events in hypertension. Recently, a new four-group left ventricular (LV) hypertrophy classification based on both LV dilatation and concentricity was proposed....
9.
Tocci G, Ferrucci A, Pontremoli R, Ferri C, Rosei E, Morganti A, et al.
J Hum Hypertens
. 2015 Feb;
29(11):696-701.
PMID: 25673112
This analysis is aimed to determine blood pressure (BP) levels and BP control rates in a large population of hypertensive patients in Italy. Data were taken from two large and...
10.
Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R, et al.
Eur Rev Med Pharmacol Sci
. 2014 May;
18(9):1295-306.
PMID: 24867507
The actual reference range of serum uric acid has been assessed according to its variations among healthy individuals. i.e. those without clinical evidence of gout. By this approach, serum uric...